Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xinguan Fuzheng Zhuanyin Decoction is a Traditional Chinese Medicine (TCM) herbal formula developed by the Guangdong Provincial Hospital of Traditional Chinese Medicine for the treatment of COVID-19. The name reflects its intended clinical purpose: "Xinguan" refers to the novel coronavirus, "Fuzheng" is a TCM principle meaning to strengthen the body's resistance or immune system, and "Zhuanyin" refers to the negative conversion of viral nucleic acid tests. The decoction was specifically evaluated in clinical trials to assess its efficacy in reducing the viral load of the SARS-CoV-2 Delta variant and accelerating the time to viral clearance in infected patients. As a multi-component herbal preparation, it is designed to modulate the host immune response while potentially exerting antiviral effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xinguan Fuzheng Zhuanyin Decoction.